PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>CJC-1295 without DAC (Mod GRF 1-29)
Minimal evidence WADA prohibitedGH / growth factors

CJC-1295 without DAC (Mod GRF 1-29)

The same GHRH 1-29 modification without the albumin-binding linker — often sold as "Mod GRF 1-29" — producing a shorter-acting GH stimulus closer to native GHRH kinetics.

CompoundCJC-1295 without DAC (Mod GRF 1-29)
CategoryGHRH analog (short-acting)
ClassGrowth Hormone and Growth Factors
Evidence tierMinimal evidence
WADA statusProhibited in sport (or falls under a prohibited class) — see the WADA reference table
Sold on this siteNo — this is a reference database

Overview

CJC-1295 without DAC (Mod GRF 1-29) is catalogued here as a ghrh analog (short-acting) and graded at the "Minimal evidence" evidence tier. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.

The same GHRH 1-29 modification without the albumin-binding linker — often sold as "Mod GRF 1-29" — producing a shorter-acting GH stimulus closer to native GHRH kinetics.

Mechanism of Action

Identical receptor pharmacology to the DAC version, but a plasma half-life measured in minutes to a couple of hours, intended for pre-injection pulsatile use.

Research and Evidence

Essentially no dedicated human clinical literature; evidence claims inherit from native GHRH pharmacology rather than trials of this exact compound.

Evidence in context: the Growth Hormone and Growth Factors class page collects the shared evidence themes and study-reading guidance for this category.

Safety and Side Effects

Uncharacterized in chronic human use; prohibited in sport.

Educational notice: this entry describes published research and, where they exist, regulator labels. It is not medical advice and not a recommendation for use. Research-grade compounds have no verified human-safety data.

Frequently Asked Questions

What is the evidence tier of CJC-1295 without DAC (Mod GRF 1-29)?

CJC-1295 without DAC (Mod GRF 1-29) is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.

Is CJC-1295 without DAC (Mod GRF 1-29) an approved medicine?

No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.

Where can I read the primary studies for CJC-1295 without DAC (Mod GRF 1-29)?

The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.

References

  1. ClinicalTrials.gov — search for CJC-1295 studies. [source]
  2. WADA Prohibited List. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement